This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Non-follicular lymphoma비여포성 림프종 (비여포성림프종)

Classification codes C83 (KCD-8 / ICD-10)
Special Copayment Reduction V193 · 5 years from the cancer patient registration date · 5% copayment
Synonyms Diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), Burkitt lymphoma, lymphoplasmacytic lymphoma, Non-follicular NHL
Adult onset Very high (median age at onset about 64 years for DLBCL; about 65 years for MCL)

Contents

A.Classification codesB.Synonyms
1.History2.Causes
3.Genetics4.General epidemiology
5.Pathophysiology6.Symptoms
7.Signs8.Screening
9.Diagnosis10.Treatment
11.Prognosis12.Prevention
13.References

A. Classification codes

CodeName
C83Non-follicular lymphoma
C83.0Small cell B-cell lymphoma
C83.1Mantle cell lymphoma (MCL)
C83.2Diffuse large B-cell lymphoma (DLBCL)
C83.3Diffuse large B-cell lymphoma, other
C83.4Immunoblastic lymphoma
C83.5Lymphoblastic (undifferentiated) lymphoma
C83.7Burkitt lymphoma
C83.8Other non-follicular lymphoma
C83.9Non-follicular lymphoma, unspecified

B. Synonyms

Non-follicular lymphoma is a comprehensive category of B-cell lymphomas that show diffuse growth without a follicular pattern. Representative subtypes include diffuse large B-cell lymphoma (DLBCL)—the most common NHL, about 30-35% of all NHL—mantle cell lymphoma (MCL), Burkitt lymphoma, and lymphoplasmacytic lymphoma (LPL). DLBCL is subdivided into the GCB type (germinal center B-cell-like) and the ABC type (activated B-cell-like), and this classification is important for prognosis and treatment selection.


1. History

The clinical history of non-follicular lymphoma, especially diffuse large B-cell lymphoma (DLBCL), parallels the development of lymphoma classification in the 20th century. The disease called "diffuse histiocytic lymphoma" in the 1950s Rappaport classification is the predecessor of today's DLBCL. With the establishment of the Rappaport classification system in 1966, lymphomas with a diffuse pattern were described separately from follicular lymphomas.

In 1982 the Working Formulation reclassified DLBCL as "intermediate- and high-grade diffuse lymphoma." In the 1994 REAL (Revised European-American Lymphoma) classification, DLBCL was recognized as an independent clinical entity. The development of the R-CHOP (rituximab + CHOP) regimen in the 1990s was a breakthrough turning point in DLBCL treatment. The GELA study (2002) demonstrated that R-CHOP was significantly superior to CHOP alone in both OS and EFS, establishing it as the standard first-line treatment for DLBCL.

In the 2000s, gene expression profiling (GEP) made it possible to subdivide DLBCL into the GCB type (favorable survival) and the ABC type (poor survival). In clinical practice, GCB and non-GCB are classified using the Hans algorithm (CD10, BCL6, MUM1 IHC). Double-hit/triple-hit lymphoma (rearrangement of MYC+BCL2, MYC+BCL6, or all three genes) was recognized as a subtype with a particularly poor prognosis and became a target for DA-EPOCH-R or R-CHOP + intensive chemotherapy.

In 2019, polatuzumab vedotin (an anti-CD79b ADC) was approved in combination with bendamustine + rituximab for relapsed/refractory DLBCL. In 2021-2022, CD19×CD3 bispecific antibodies (glofitamab, epcoritamab) and CD19-targeted CAR-T cells (axi-cel, tisa-cel, liso-cel) received approval for third-line or later treatment of relapsed/refractory DLBCL. In 2024, the role of bispecific antibodies and CAR-T has been expanding to second-line or later treatment as well. In mantle cell lymphoma (MCL), the introduction of BTK inhibitors (ibrutinib, zanubrutinib, acalabrutinib) and venetoclax has greatly changed the treatment landscape.

2. Causes

EBV: In EBV-positive DLBCL—especially EBV+ DLBCL NOS occurring in older adults and immunosuppression-associated DLBCL—EBV infection plays an important role in carcinogenesis. EBV LMP1 activates the NF-κB and PI3K/AKT pathways to promote B-cell transformation.

HIV infection: In HIV-positive patients, the risk of DLBCL increases 50-100 times. HIV-associated DLBCL has a high proportion of EBV association and is often associated with body cavity-based primary effusion lymphoma (PEL) or HHV-8-associated multicentric Castleman disease.

H. pylori (MALT lymphoma): H. pylori infection is the main cause of gastric MALT lymphoma (C84, marginal zone lymphoma), and the unique cases in which gastric MALT lymphoma reaches remission with H. pylori eradication therapy have also played an important role in understanding DLBCL. Gastric MALT lymphoma can transform into DLBCL without treatment.

Autoimmune diseases: The risk of NHL (especially MALT lymphoma and DLBCL) is increased in Sjögren syndrome, Hashimoto thyroiditis, and rheumatoid arthritis. Persistent B-cell activation due to chronic antigen stimulation is presumed to contribute.

Burkitt lymphoma (C83.7): Endemic Burkitt lymphoma occurs in African children through the combined action of EBV (nearly 100%) and malaria (Plasmodium falciparum). Sporadic Burkitt lymphoma occurs in adolescents and young adults and has a low proportion of EBV association. AIDS-associated Burkitt lymphoma involves immunodeficiency and EBV infection.

Mantle cell lymphoma (MCL): MCL often occurs without specific environmental risk factors. However, associations with exposure to organic solvents and herbicides have been reported to a limited extent. NOTCH1/2, TP53, and CCND1 mutations contribute to MCL carcinogenesis.

3. Genetics

DLBCL cell-of-origin (COO) classification:

MYC/BCL2/BCL6 double/triple-hit lymphoma (DHL/THL): The simultaneous presence of MYC rearrangement (8q24) and BCL2 rearrangement (18q21) defines "double-hit" DLBCL, and triple rearrangement (+BCL6) is "triple-hit." This subtype is classified separately as high-grade B-cell lymphoma (HGBL), responds poorly to R-CHOP (CR rate 40-50%), and has a very poor prognosis. DA-EPOCH-R or R-CHOP + autologous hematopoietic stem cell transplantation is attempted.

Mantle cell lymphoma (MCL): The t(11;14)(q13;q32)/CCND1-IGH translocation is found in about 95% of MCL, and cyclin D1 overexpression causes abnormal cell cycle regulation. TP53 mutation, CDKN2A/B loss, and NOTCH1/2 mutations are associated with poor prognosis. The blastoid variant has frequent TP53 mutations and a particularly poor prognosis. The MIPI (MCL International Prognostic Index) classifies patients into low-, intermediate-, and high-risk groups. Small-cell indolent MCL ("in situ" MCL) can be observed without clinical treatment.

Burkitt lymphoma: The t(8;14)(q24;q32)/MYC-IGH translocation (or the t(2;8), t(8;22) variants) causes pathological MYC overexpression. MYC is a transcription factor that broadly regulates cell proliferation, metabolism, and apoptosis, and the tumor shows extreme hyperproliferation, with a Ki-67 proliferation index reaching 95-100%.

Pharmacogenomics: MYD88 L265P (predicts ibrutinib response in ABC DLBCL), CD19 expression (confirms CAR-T indication), BCL2 overexpression (venetoclax target), CD20 expression (rituximab/obinutuzumab target), CD79b (polatuzumab vedotin target), PD-L1/PD-L2 (immune checkpoint inhibitors), MSI-H/TMB-H (pembrolizumab)

4. General epidemiology

DLBCL: The most common NHL worldwide, accounting for about 30-35% of all NHL. About 30,000 people are newly diagnosed annually in the United States. The median age at onset is about 64 years, and it is slightly more common in men. In Korea as well, DLBCL is the most common lymphoma, accounting for about 35-40% of all NHL according to national cancer registry and Korean Lymphoma Study Group (KCSG) data. In Korea, about 3,000-4,000 people are diagnosed with DLBCL annually.

MCL: About 5-7% of all NHL; about 3,000-4,000 people are diagnosed annually in the United States. The median age at onset is about 60-65 years, with male predominance (male:female = 3-4:1). Incidence in Asia is lower than in the West. At diagnosis, more than 90% are at an advanced stage (III-IV), and involvement of the bone marrow and blood is common.

Burkitt lymphoma: About 1-5% of all NHL. The endemic form occurs predominantly in children in sub-Saharan Africa. The sporadic form occurs worldwide and is a common high-grade lymphoma in children/adolescents. Adult Burkitt lymphoma is relatively rare. In Korea, the sporadic form predominates and is an important cause of pediatric NHL.

5. Pathophysiology

DLBCL pathogenesis: DLBCL derives from germinal center B cells (GCB type) or post-germinal center activated B cells (ABC type). In the GCB subtype, BCL2/IGH translocation and EZH2 mutations arise during the process of somatic hypermutation. BCL2 overexpression inhibits apoptosis, and when additional MYC overexpression or BCL6 rearrangement promotes rapid cell proliferation, the disease progresses to aggressive lymphoma. In the ABC subtype, the MYD88 L265P mutation persistently activates TLR signaling, constitutively activating NF-κB. NF-κB activation through CD79A/B ITAM signaling and CARD11 is also a key mechanism of the ABC subtype.

MCL pathogenesis: When cyclin D1 is overexpressed due to the t(11;14) translocation in mantle zone B cells, it promotes the G1/S cell cycle transition via the CDK4/6-Rb-E2F pathway. Loss of TP53 and INK4a/ARF (CDKN2A) releases cell cycle inhibition, accelerating cell proliferation. SOX11 expression blocks the differentiation of MCL, and SOX11-negative MCL tends to show an indolent course. ATM (ataxia telangiectasia mutated) mutations interfere with the DNA damage response, increasing genomic instability.

Burkitt lymphoma pathogenesis: With the MYC/IGH translocation, MYC comes under the influence of the IGH enhancer and is constitutively overexpressed. MYC activates hundreds of target genes involved in cell proliferation, metabolism (Warburg effect), protein synthesis, and regulation of apoptosis. BCL2 is usually not expressed, so p53-mediated apoptosis is relatively preserved, which explains the high response rate to intensive chemotherapy such as DA-EPOCH-R or hyper-CVAD. ID3, TCF3, and CCND3 mutations have been identified as additional oncogenic changes in Burkitt lymphoma.

6. Symptoms

DLBCL symptoms: Rapidly enlarging painless lymphadenopathy is the most common presenting symptom. Extranodal lesions (extranodal DLBCL) occur in about 40%, with the gastrointestinal tract (especially the stomach), central nervous system, testis, bone, and skin as common sites. B symptoms (fever, night sweats, weight loss) occur in about 30-40%. Testicular DLBCL presents as testicular enlargement and carries a high risk of contralateral testicular and CNS spread, so prophylactic treatment is needed.

MCL symptoms: Most cases are diagnosed at an advanced stage, and generalized lymphadenopathy, splenomegaly, and bone marrow involvement are common. Gastrointestinal MCL causes polyposis, leading to bowel obstruction, diarrhea, and bloody stools. A leukemic presentation (circulating MCL cells) occurs in about 25%. "Indolent MCL," discovered incidentally at asymptomatic checkups, is SOX11-negative and can be observed without treatment.

Burkitt lymphoma symptoms: An abdominal mass (mesenteric lymph nodes, small intestine, ileocecal region) is the most common presenting site in sporadic Burkitt lymphoma. Jaw mass (characteristic of endemic Burkitt lymphoma). The risk of tumor lysis syndrome (TLS) is very high, so preventive measures are essential before starting treatment. Central nervous system involvement (about 10-30%) can cause headache, cranial nerve palsy, and seizures.

7. Signs

DLBCL: Rapidly enlarging lymphadenopathy (doubling in size within weeks), splenomegaly, hepatomegaly. Ascites with peritoneal involvement. Cranial nerve palsy and altered mental status with CNS involvement. Elevated LDH (reflecting tumor burden and proliferation index), elevated β2-microglobulin. IPI (International Prognostic Index) score: 5 factors—age (>60), elevated LDH, ECOG PS 2 or higher, Ann Arbor stage III-IV, number of extranodal sites (≥2). 0-1 points is classified as low risk and 4-5 points as high risk.

MCL: Splenomegaly is prominent, and hepatomegaly is also common. MCL cells (irregular nuclei, larger and smaller than mature lymphocytes) may be seen on blood smear. Reduced performance status (ECOG PS ≥2), elevated LDH, and WBC >10,000/μL are MIPI high-risk factors.

8. Screening

There is no general population screening for non-follicular lymphoma. Strategies for early detection in high-risk groups are important. Monitoring CD4 count and viral load in HIV-positive people and EBV serological surveillance in immunosuppressed transplant patients can capture early warning signs of lymphoma development. In MCL, asymptomatic SOX11-negative small lymphocytic MCL sometimes exists before diagnosis, so MCL must be differentiated by flow cytometry in patients with incidentally discovered lymphocytosis in the blood.

Post-treatment surveillance: After complete remission of DLBCL, clinical evaluation and CT every 3-6 months for 2 years. Monitoring of ctDNA (MRD, minimal residual disease) for early detection of relapse is under investigation. Burkitt lymphoma requires intensive surveillance for 1-2 years after the end of treatment (high-risk relapse period).

9. Diagnosis

Tissue biopsy: Excisional biopsy or core needle biopsy (obtaining sufficient tissue is essential). Combined application of flow cytometry, IHC, and FISH.

DLBCL IHC panel:

MCL IHC panel: CD5+, CD20+, CD23- (on flow), Cyclin D1++ (nuclear positive, strong), SOX11+/-, Ki-67 (proliferation index >30% indicates high-grade/blastoid).

Burkitt lymphoma IHC/FISH: CD20+, CD10+, BCL6+, BCL2- (an important differentiating criterion), Ki-67 95-100%, MYC+ (IHC), FISH confirming isolated MYC rearrangement (Burkitt is confirmed only in the absence of BCL2/BCL6 rearrangement; if both are present, double-hit).

Molecular tests: FISH (MYC, BCL2, BCL6), NGS panel (MYD88, CD79B, CARD11, TP53, NOTCH, EZH2), COO classification (GEP or Hans algorithm). Whole-body staging by PET-CT. Bone marrow biopsy. Evaluation of CNS involvement (cerebrospinal fluid examination and brain MRI in high-risk DLBCL).

10. Treatment

DLBCL first-line treatment

R-CHOP (6 cycles): Standard first-line treatment for DLBCL. Overall response rate about 80%, complete remission rate 70-75%. In the IPI low-risk group, R-CHOP 4 cycles + radiation therapy (consolidated RT) is considered. Polatuzumab vedotin + R-CHP (Pola-R-CHP, POLARIX study): Improved progression-free survival compared with conventional R-CHOP (2 years 76.7% vs 70.2%). In intermediate- and high-risk DLBCL (IPI 2-5 points), Pola-R-CHP is currently trending toward being the preferred recommendation. DA-EPOCH-R: Considered in double-hit/triple-hit DLBCL. A more intensive regimen, but a survival benefit over R-CHOP has not been consistently demonstrated. CNS prophylaxis: High-dose methotrexate given as prophylactic intrathecal injection or systemically in CNS IPI high risk (4-6 points), testicular DLBCL, and renal/adrenal involvement.

Relapsed/refractory DLBCL

MCL treatment

Burkitt lymphoma treatment

11. Prognosis

Subtype5-year survivalNotes
DLBCL (IPI 0-1, R-CHOP)About 80-90%Low-risk group
DLBCL (IPI 4-5, R-CHOP)About 40-50%High-risk groups
Double-hit DLBCLAbout 25-40%Poor response to R-CHOP
MCL (MIPI low risk)About 60-70%Median OS 5-7 years
MCL (MIPI high risk)About 20-30%
Burkitt lymphoma (pediatric, intensive treatment)About 80-95%Excellent treatment response
Burkitt lymphoma (adult)About 50-70%Increased toxicity in older adults

In DLBCL, COO (GCB vs ABC) classification, MYC/BCL2 protein double expression (DEL), double/triple-hit status, IPI score, and PET response after R-CHOP are major prognostic factors. In MCL, the Ki-67 proliferation index (>30% is unfavorable), TP53 mutation, MIPI score, and SOX11 expression determine prognosis.

12. Prevention

There is no specific prevention for non-follicular lymphoma. Prevention of HIV infection and early treatment (ART) are most effective in preventing HIV-associated DLBCL and Burkitt lymphoma. In immunosuppressed transplant patients, EBV surveillance and minimizing immunosuppression help prevent EBV-associated lymphoproliferative disorders. Diagnosis and eradication of H. pylori infection contribute to preventing gastric MALT lymphoma and some DLBCL. Appropriate immunosuppressive treatment of autoimmune diseases may lower the risk of associated lymphoma. In high-risk DLBCL, prophylactic intrathecal chemotherapy or systemic high-dose methotrexate to prevent CNS relapse is recommended in clinical guidelines.


13. References

  1. Coiffier B, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235-242.
  2. Tilly H, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med. 2022;386(4):351-363.
  3. Locke FL, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma. Nat Med. 2019;25(8):1215-1218.
  4. Dickinson MJ, et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2022;387(24):2220-2231.
  5. Dreyling M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma. Lancet. 2016;387(10020):770-778.
  6. Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl J Med. 2021;384(9):842-858.
  7. Schmitz R, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378(15):1396-1407.
  8. Korean Society of Hematology. Clinical practice guideline for diffuse large B-cell lymphoma. 2023.
  9. NCCN Clinical Practice Guidelines: B-Cell Lymphomas. Version 4.2025.
  10. Korean Cancer Study Group (KCSG). Lymphoma Registry in Korea. Blood Res. 2023.